The severity of COVID-19 respiratory failure in some patients has taken the medical community by surprise. And in response, that community has been trying just about anything that seems reasonable in an effort to improve outcomes — and in some cases as last-resort measures to save lives.
Nitric oxide may not be done yet. The colorless, odorless gas, inhaled through a mask or even from a small “flute,” is now being tested as an experimental treatment for COVID-19. It may also prove helpful in protecting healthcare workers on the front line of the pandemic from getting sick.
Medical researchers are testing whether inhaled nitric oxide could help treat patients with the coronavirus.
Researchers at Massachusetts General Hospital (MGH) are studying whether inhaling a gas called nitric oxide can help treat patients with COVID-19, or even prevent people from getting the disease.
Nitric oxide has been considered a miracle drug for helping oxygen-starved newborns
A “remarkable” drug known to relax blood vessels could help coronavirus patients with severely damaged lungs and will be tested at Massachusetts General Hospital, making it the first center in the nation to rigorously test nitric oxide for novel coronavirus.
Critical care and emergency medicine faculty at the LSU Health Shreveport Department of Medicine join the Department of Anesthesia at Massachusetts General Hospital (MGH) and the Division of Cardiology in the Department of Medicine at University of Alabama-Birmingham (UAB) as being among the first centers in the United States to enroll patients in an international study testing using inhaled nitric oxide to improve outcomes for COVID-19 patients with severely damaged lungs; using gas to effectively “kill” coronavirus in the lungs and improve delivery of oxygen to injured tissues.
Doctors from around the world are seeing if the gas that gave us the ‘little blue pill’ will also help treat the novel coronavirus as it continues to spread.
Scientists in Massachusetts, Italy, and elsewhere are experimenting with a familiar medical treatment for the new problem of covid-19. They’ve begun clinical trials meant to find out whether inhaled nitric oxide can save people who are severely sick from the new coronavirus. This treatment might even be used preventatively to keep health care workers infection-free.
Never before, scientists say, have so many of the world’s researchers focused so urgently on a single topic. Nearly all other research has ground to a halt.
Third Pole Therapeutics CEO Bill Athenson sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. The company, based in Waltham, Massachusetts, is developing transformative cardio-pulmonary therapies such as its FDA-approved pulmonary vasodilator to treat hypoxic respiratory failure in newborns.
Arlington, MA – October 30, 2019 – Third Pole Therapeutics, a privately held company developing and delivering transformative life-saving cardio-pulmonary therapies, has named seasoned healthcare executive Bill Athenson as its new Chief Executive Officer.
Each year, roughly 100,000 babies worldwide are diagnosed with a life-threatening condition called persistent pulmonary hypertension of the newborn (PPHN). In infants with PPHN, blood does not circulate properly through the lungs, and sufficient oxygen does not reach the heart, brain and other major organs. Yet, despite the proven effectiveness of inhaled nitric oxide (iNO) as a life-saving treatment for PPHN, access to it by patients has been severely limited—in part because of its expensive, unwieldy system of delivery…
Third Pole Therapeutics, a privately held company developing and delivering transformative cardio-pulmonary therapies, announced today that it has entered into a strategic collaboration to work with Actelion Pharmaceuticals Ltd, a Janssen pharmaceutical company of Johnson & Johnson…
The technologies that improve lives in the world’s underserved communities are born as prototypes that evolve through testing and tinkering in workshops, laboratories and garages…
A new device, the Third Pole is able to generate nitric oxide (NO) from the air that can help improve oxygenation and treat pulmonary hypertension a common problem among some newborns…
The Third Pole makes its own nitric oxide to treat pulmonary hypertension,
no tanks required….
Inhaled nitric oxide (iNO) relaxes blood vessels in the lungs and is an important and life-saving treatment for pulmonary hypertension. Current iNO delivery solutions are estimated to cost $2,800 per day and rely on compressed gas delivery which limits accessibility and applicability of this technology worldwide…
Third Pole has won a Johnson & Johnson Innovation award for a lighter device that provides an unlimited supply of nitric oxide (NO) to patients with pulmonary hypertension (PH) and other respiratory conditions…
Volume 60, 2016, Pages 16-23
Binglan Yu, Aron H. Blaesi, Noel Casey, Grigory Raykhtsaum, Luca Zazzeron, Rosemary Jones, Alexander Morrese, Danil Dobrynin, Rajeev Malhotra, Donald B. Bloch, Lee E. Goldstein, Warren M. Zapol
In the 25 years since discovering a life-saving therapy consisting of breathing low levels of the gas nitric oxide—which is still the only selective inhaled pulmonary vasodilator—Massachusetts General Hospital (MGH) anesthesiologist Warren M. Zapol, MD, and his MGH team has given clinicians a treatment to simply save the lives of vast numbers of hypoxic newborns (“blue babies”)and prevent or reverse pulmonary hypertension in hundreds of thousands of adults during surgery…